RICHARD K. ALBERT, M.D.; THOMAS R. MARTIN, M.D.; STEVEN W. LEWIS, M.D.
▸Requests for reprints should be addressed to Richard K. Albert, M.D.; Veterans Administration Medical Center, 4435 Beacon Avenue South; Seattle, WA 98108.
ALBERT RK, MARTIN TR, LEWIS SW. Controlled Clinical Trial of Methylprednisolone in Patients with Chronic Bronchitis and Acute Respiratory Insufficiency. Ann Intern Med. 1980;92:753-758. doi: 10.7326/0003-4819-92-6-753
Download citation file:
Published: Ann Intern Med. 1980;92(6):753-758.
To evaluate the role of corticosteroids as treatment for acute exacerbations of chronic obstructive pulmonary disease, we conducted a double-blind, randomized, placebo-controlled trial in 44 consecutive patients with chronic bronchitis and severe airflow obstruction. All were hospitalized with acute respiratory insufficiency from acute bronchitis. Patients with asthma, atopy, or pneumonia were excluded. Treatment consisted of intravenous aminophylline, inhaled isoproterenol, antibiotics, and either methylprednisolone, 0.5 mg/kg of body weight, or placebo every 6 h intravenously for 72 h. Bedside spirometry was done before and after bronchodilator inhalation three times daily. The methylprednisolone-treated group had a greater improvement in both prebronchodilator and postbronchodilator forced expiratory volume in 1 second (P < 0.001). More patients with large improvements in their prebronchodilator or postbronchodilator flow rates, or both (≥ 40% by 72 h), received methylprednisolone (P < 0.01). Methylprednisolone improved airflow more than placebo when added to standard therapy in patients with chronic bronchitis and acute respiratory insufficiency.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only